



Do you have any Publications Proving the Survival Data on the DC Bead Irinotecan.

- **Professor Fiorentini, Professor of Medical Oncology at the Department of Oncology at the San Giuseppe Hospital, Empoli, Florence, is evaluating the DC Bead loaded with Irinotecan in a prospective phase II study in patients with liver metastases from mCRC.**
- **Twenty patients with liver metastases, Stage I, II & III have been treated with a dose of 100mgs of Irinotecan.**
- **At the reporting date the median overall survival was 160 days (range 50 – 245), in the no TACE group it was 99 days (range 48 – 150).**

Survival (days)



Ref: Data presented at 2007 Gastrointestinal Cancers Symposium (ASCO-GI)